128715-Thumbnail Image.png

Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as…

Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as serotype replacement, limited coverage and high costs. A recombinant live vector vaccine delivering protective antigens is a promising way to achieve this goal. In this review, we discuss the researches using live recombinant vaccines, mainly live attenuated Salmonella and lactic acid bacteria, to deliver pneumococcal antigens. We also discuss both the limitations and the future of these vaccines.

Copyright Statement
    • Reuse Permissions
    • Downloads
    PDF (755 KB)

    Details

    Title
    • Development of Streptococcus Pneumoniae Vaccines Using Live Vectors
    Contributors
    Date Created
    2015-01-07
    Resource Type
  • Text
    • Collections this item is in
    ASU Scholarship Showcase
    Identifier
    • Digital object identifier: 10.3390/vaccines2010049
    • International standard serial number
      2076-393X

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Wang, S., & Iii, R. C. (2014). Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines, 2(1), 49-88. doi:10.3390/vaccines2010049

    Machine-readable links